Cherif Abdelmalek, MD
Medical Oncology · Nashua, NHNPI 1922396753
Payments from drug & device makers
What this record shows
This record is dominated by education: $233 of the $281 with a category attached, or 83.1%. 8 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 35.6% of the total. That places this record below the midpoint for medical oncology clinicians in NH, where the typical reported total is $368.
Across 10 payments — averaging $28.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$100
- Mirati Therapeutics, Inc.$60
- Beigene USA, Inc.$27
- Daiichi Sankyo Inc.$27
- Genentech USA, Inc.$21
- Merck$18
- plus $28 from 2 others
What the payments were for
- Food & beverage$4717%
- Education$23383%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $100 |
| Mirati Therapeutics, Inc. | 3 | $60 |
| Beigene USA, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Genentech USA, Inc. | 1 | $21 |
| Merck | 1 | $18 |
| Pfizer | 1 | $16 |
| Seagen Inc. | 1 | $12 |
How this compares
$281 in reported general payments places this provider in the 45th percentile of 20 medical oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $29,146 |
| XareltoRivaroxaban | 19 | $16,830 |
| ValacyclovirValacyclovir Hcl | 20 | $993 |
| Ondansetron Hcl | 19 | $844 |
| Hydroxyurea | 25 | $662 |
| Dexamethasone | 82 | $637 |
| Acyclovir | 54 | $597 |
| Prochlorperazine Maleate | 14 | $477 |
| Olanzapine | 54 | $473 |
| Oxycodone Hcl | 36 | $400 |
| Fluconazole | 21 | $279 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $245 |
| Letrozole | 16 | $212 |
| Methylphenidate Hcl | 13 | $180 |
| Ciprofloxacin Hcl | 31 | $179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16 | $29,14645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 20 medical oncology providers in New Hampshire.
Other medical oncology in Nashua
- Can WangNashua$108
- Peter KaufmanLebanon$651K
- James RigasLebanon$251K
- Tyler CurielLebanon$29K
- Charles GaulinLebanon$20K
- Linda VahdatLebanon$20K
- Barbara CivielloDover$11K
- Jakow DienerBethlehem$1K
- Tara KaufmannLebanon$656
- Panagiotis FidiasExeter$457
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.